Loading...
Loading...
In a report published Friday, Credit Suisse analyst Michael Nemeroff downgraded the rating on
CovisintCOVS from Outperform to Neutral, and lowered the price target from $17.00 to $8.00.
In the report, Credit Suisse noted, “COVS negatively preannounced that F4Q14 (Mar) revenue is expected to be down 1-7% yr/yr ($24.0-25.5M), which is well below prior guidance of +6-8% yr/yr ($27.3-27.8M). The weaker FQ4 revenue outlook was attributed to sales execution and late-stage pipeline conversion issues as well as greater than expected decline in legacy EDI subscription revenue. Additionally, board member Sam Inman will now serve as the interim CEO and mgmt expects to hire a new head of sales in the near-term. We lower our F2014 and F2015 revenue / EPS ests to $97.1M / $(0.43) and $100.8M / $(0.47), respectively, from $100.1M / $(0.36) and $114.8M / $(0.17), reflecting a much lower revenue run-rate.”
Covisint closed on Thursday at $7.78.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in